Literature DB >> 30971760

MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells.

Ren-Ming Yang1,2, Devathri Nanayakkara3, Murugan Kalimutho3, Partha Mitra1,4, Kum Kum Khanna3, Eloise Dray5,6,7, Thomas J Gonda8,9.   

Abstract

Over 70% of human breast cancers are estrogen receptor-positive (ER+), most of which express MYB. In these and other cell types, the MYB transcription factor regulates the expression of many genes involved in cell proliferation, differentiation, tumorigenesis, and apoptosis. So far, no clear link has been established between MYB and the DNA damage response in breast cancer. Here, we found that silencing MYB in the ER+ breast cancer cell line MCF-7 led to increased DNA damage accumulation, as marked by increased γ-H2AX foci following induction of double-stranded breaks. We further found that this was likely mediated by decreased homologous recombination-mediated repair (HRR), since silencing MYB impaired the formation of RAD51 foci in response to DNA damage. Moreover, cells depleted for MYB exhibited reduced expression of several key genes involved in HRR including BRCA1, PALB2, and TOPBP1. Taken together, these data imply that MYB and its targets play an important role in the response of ER+ breast cancer cells to DNA damage, and suggest that induction of DNA damage along with inhibition of MYB activity could offer therapeutic benefits for ER+ breast cancer and possibly other cancer types.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30971760     DOI: 10.1038/s41388-019-0789-3

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage.

Authors:  E Raderschall; E I Golub; T Haaf
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 2.  MYB function in normal and cancer cells.

Authors:  Robert G Ramsay; Thomas J Gonda
Journal:  Nat Rev Cancer       Date:  2008-07       Impact factor: 60.716

3.  Characterization of alternate and truncated forms of murine c-myb proteins.

Authors:  R G Ramsay; S Ishii; Y Nishina; G Soe; T J Gonda
Journal:  Oncogene Res       Date:  1989

Review 4.  Role and potential for therapeutic targeting of MYB in leukemia.

Authors:  D R Pattabiraman; T J Gonda
Journal:  Leukemia       Date:  2012-08-09       Impact factor: 11.528

5.  Functional, morphological, and apoptotic alterations in skeletal muscle of ARC deficient mice.

Authors:  Andrew S Mitchell; Ian C Smith; Daniel Gamu; Stefan Donath; A Russell Tupling; Joe Quadrilatero
Journal:  Apoptosis       Date:  2015-03       Impact factor: 4.677

6.  High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.

Authors:  Rachel A Sanford; Juhee Song; Angelica M Gutierrez-Barrera; Jessica Profato; Ashley Woodson; Jennifer Keating Litton; Isabelle Bedrosian; Constance T Albarracin; Vicente Valero; Banu Arun
Journal:  Cancer       Date:  2015-08-17       Impact factor: 6.860

Review 7.  DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology.

Authors:  Kahlin Cheung-Ong; Guri Giaever; Corey Nislow
Journal:  Chem Biol       Date:  2013-05-23

8.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

Review 9.  Directly targeting transcriptional dysregulation in cancer.

Authors:  Thomas J Gonda; Robert G Ramsay
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

10.  TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.

Authors:  Pavel Moudry; Kenji Watanabe; Kamila M Wolanin; Jirina Bartkova; Isabel E Wassing; Sugiko Watanabe; Robert Strauss; Rune Troelsgaard Pedersen; Vibe H Oestergaard; Michael Lisby; Miguel Andújar-Sánchez; Apolinar Maya-Mendoza; Fumiko Esashi; Jiri Lukas; Jiri Bartek
Journal:  J Cell Biol       Date:  2016-01-25       Impact factor: 10.539

View more
  8 in total

1.  Transcription factor c-Myb: novel prognostic factor in osteosarcoma.

Authors:  Kamila Říhová; Monika Dúcka; Iva Staniczková Zambo; Ladislava Vymětalová; Martin Šrámek; Filip Trčka; Jan Verner; Stanislav Drápela; Radek Fedr; Tereza Suchánková; Barbora Pavlatovská; Eva Ondroušková; Irena Kubelková; Danica Zapletalová; Štěpán Tuček; Peter Múdry; Dagmar Adámková Krákorová; Lucia Knopfová; Jan Šmarda; Karel Souček; Lubor Borsig; Petr Beneš
Journal:  Clin Exp Metastasis       Date:  2022-01-07       Impact factor: 5.150

2.  Paths and pathways that generate cell-type heterogeneity and developmental progression in hematopoiesis.

Authors:  Juliet R Girard; Lauren M Goins; Dung M Vuu; Mark S Sharpley; Carrie M Spratford; Shreya R Mantri; Utpal Banerjee
Journal:  Elife       Date:  2021-10-29       Impact factor: 8.140

3.  An Unconventional Melanin Biosynthesis Pathway in Ustilago maydis.

Authors:  Esmeralda Z Reyes-Fernández; Yi-Ming Shi; Peter Grün; Helge B Bode; Michael Bölker
Journal:  Appl Environ Microbiol       Date:  2021-01-15       Impact factor: 4.792

4.  Hsa_circ_0015326 Promotes the Proliferation, Invasion and Migration of Ovarian Cancer Through miR-127-3p/MYB.

Authors:  Cuiying Zhang; Wei Liu; Fei Li; Yang Feng; Yunyun Li; Jia Wang
Journal:  Cancer Manag Res       Date:  2021-03-10       Impact factor: 3.989

5.  Discovering Genotype Variants in an Infant with VACTERL through Clinical Exome Sequencing: A Support for Personalized Risk Assessment and Disease Prevention.

Authors:  Gloria Pelizzo; Luigi Chiricosta; Emanuela Mazzon; Gian Vincenzo Zuccotti; Maria Antonietta Avanzini; Stefania Croce; Mario Lima; Placido Bramanti; Valeria Calcaterra
Journal:  Pediatr Rep       Date:  2021-01-05

Review 6.  MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.

Authors:  Ylenia Cicirò; Arturo Sala
Journal:  Oncogenesis       Date:  2021-02-26       Impact factor: 7.485

7.  WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.

Authors:  Amanpreet Kaur; Jun Yi Stanley Lim; Sugunavathi Sepramaniam; Siddhi Patnaik; Nathan Harmston; May Ann Lee; Enrico Petretto; David M Virshup; Babita Madan
Journal:  EMBO Mol Med       Date:  2021-03-04       Impact factor: 12.137

8.  Functional and structural analysis of non-synonymous single nucleotide polymorphisms (nsSNPs) in the MYB oncoproteins associated with human cancer.

Authors:  Shu Wen Lim; Kennet JunKai Tan; Osman Mohd Azuraidi; Maran Sathiya; Ee Chen Lim; Kok Song Lai; Wai-Sum Yap; Nik Abd Rahman Nik Mohd Afizan
Journal:  Sci Rep       Date:  2021-12-17       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.